SPEECH by Dr. Ray Busuttil, Director General (Public Health Regulation) AT THE OFFICIAL LAUNCH OF THE MALTESE NATIONAL HAEMOVIGILANCE SYSTEM, ORGANISED BY THE DEPARTMENT OF HEALTH CARE SERVICES STANDARDS - PALAZZO CASTELLANIA – 27 APRIL 2009
The treatment of patients with blood and blood products has become an important issue in quality care medicine. Blood transfusion is being used in the treatment of various conditions as prescribed in all clinical specialties.
However, blood transfusion is not without risks and can potentially be the cause of reactions and transmission of infectious diseases. A blood supply of high quality and in sufficient quantity requires not only the contribution of donors, good donor selection criteria, high quality standards in the whole process of blood production, optimal use of blood and blood products in clinical care, safe transfusion practices but also haemovigilance: the vigilance of adverse reactions and events related to blood transfusion.
Haemovigilance means a set of organised surveillance procedures relating to serious adverse or unexpected events or reactions in donors and recipients, and the epidemiological follow-up of donors.
The aim of haemovigilance is to detect and to analyse all untoward effects of blood transfusion in order to correct their cause and prevent recurrence and to improve the safety of blood transfusion.
Haemovigilance is important because quality in our blood and blood components is a continuous investment we owe to our patients and we pride ourselves in its quality and safety. The Department of Health Care Services Standards is committed in ensuring that there are effective quality systems in place that guarantee consistent quality and the safety of blood transfusion throughout the whole transfusion chain from the recruitment of blood donors, the processing of blood and blood products, the transfusion of blood and blood products and follow-up of the recipients and donor.
The reporting of adverse reactions and events is important from the organizational point of view as learning from reporting is the hallmark of a learning organization. An ‘open and blame free culture’ that emphasises the need for healthcare professionals and organisations to explore the underlying reasons for errors within a supportive environment, with the ultimate aim of improving patient care and safety needs to be encouraged.
The establishment of this haemovigilance system is also important in view of the legal obligations imposed by the Blood and Transplants Act (Act IV of 2006) and the L.N. 273 of 2006, HUMAN BLOOD AND TRANSPLANTS ACT, 2006 (Act No. IV OF 2006) Traceability Requirements and Notification of Serious Adverse Reactions and Events Regulations, 2006 (transposing Directive 2005/61/EC and implementing Directive 2002/98/EC as regards traceability requirements). As health care professionals, we have a professional responsibility and a legal obligation to adhere to these statutory requirements.
The Public Health Regulatory Division is the necessary institutionalised framework to ensure implementation of these measures. The Department of Health Care Services Standard within this Division is taking the lead in reinforcing this system of reporting of adverse reactions and events related to blood transfusion.
During the year 2008, there were several developments, including the establishment of a Haemovigilance Unit, the setting of the institutional structures and systems for reporting and participation in the Haemovigilance training module organised as part of the twinning project between the Malta Medicines Authority and the Netherlands. Malta became a full member of the European Haemovigilance Network during this same year and benefited from a grant directed towards training of staff at Mater Dei Hospital related to the national haemovigilance system.
As part of the reporting obligations to the EU Commission, the first National Haemovigilance Report for the year 2007 was published during 2008. The report for 2008 is being presently compiled for transmission to the EU Commission by June 2009.
It is with pride and satisfaction to refer to the 2007 report as an index of the high quality standards in our national blood and blood products. During 2007, there were no cases of transfusion-transmitted infections. There were no deaths related to blood transfusion.
None of the reported reactions were related to the quality and safety of blood.
During 2007, a total of 14125 units of whole blood were collected and a total of 355 aphaeresis collections were performed. A total of 19597 units of blood components were distributed.
| Component | Number of Units Distributed |
| Red blood cells | 13560 |
| Aphaeresis platelets | 353 |
| Pooled platelets | 641 |
| Filtered fresh frozen plasma | 3970 |
| Filtered cryoprecipitate | 1073 |
| TOTAL COMPONENTS DISTRIBUTED | 19597 |
Table 1.
Units of blood components distributed by the blood establishment during 2007
Out of this high throughput, only 29 adverse reactions related to blood transfusions were reported. Most reactions that were reported were febrile reactions and allergic reactions and of which only one involved what is referred to as a serious adverse reaction. This serious adverse reaction was not related to the quality of blood.
| Component | Number of Units Distributed |
| Red blood cells | 13560 |
| Aphaeresis platelets | 353 |
| Pooled platelets | 641 |
| Filtered fresh frozen plasma | 3970 |
| Filtered cryoprecipitate | 1073 |
| TOTAL COMPONENTS DISTRIBUTED | 19597 |
Table 2:
Transfusion Reactions Reported to the National Haemovigilance Office during 2007.
* reportable to the EU Commission
In Malta, the rate of serious adverse reactions related to blood transfusions (reactions that are reportable to the European Commission) is very low (5.1 reactions per 100,000 units of blood components distributed). These statistics illustrate clearly that the quality and safety of blood and blood components in Malta is excellent.
Whilst I cannot emphasis more than enough that our patients deserve nothing but the best, especially when it comes to the quality of blood, I auger all present the very best of learning during this seminar.
DOI – 27.04.2009
Stqarrijiet Oħra:
PR261985
STQARRIJA MILL-UFFIĊĊJU TAD-DEPUTAT PRIM MINISTRU U MINISTERU GĦAS-SAĦĦA U ...
PR261984